96 related articles for article (PubMed ID: 38456253)
21. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
22. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
23. Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer.
Avilés-Salas A; Flores-Estrada D; Lara-Mejía L; Catalán R; Cruz-Rico G; Orozco-Morales M; Heredia D; Bolaño-Guerra L; Soberanis-Piña PD; Varela-Santoyo E; Cardona AF; Arrieta O
Thorac Cancer; 2022 Dec; 13(23):3362-3373. PubMed ID: 36317227
[TBL] [Abstract][Full Text] [Related]
24. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
[TBL] [Abstract][Full Text] [Related]
25. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Popat S; Liu SV; Scheuer N; Gupta A; Hsu GG; Ramagopalan SV; Griesinger F; Subbiah V
JAMA Netw Open; 2022 May; 5(5):e2214046. PubMed ID: 35612853
[TBL] [Abstract][Full Text] [Related]
26. Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis.
Tonse R; Rubens M; Appel H; Tom MC; Hall MD; Odia Y; McDermott MW; Ahluwalia MS; Mehta MP; Kotecha R
Neurooncol Adv; 2021; 3(1):vdab166. PubMed ID: 34988451
[TBL] [Abstract][Full Text] [Related]
27. First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
Reck M; Remon J; Hellmann MD
J Clin Oncol; 2022 Feb; 40(6):586-597. PubMed ID: 34985920
[TBL] [Abstract][Full Text] [Related]
28. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Dai L; Jin B; Liu T; Chen J; Li G; Dang J
EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
[TBL] [Abstract][Full Text] [Related]
29. Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhao W; Jiang W; Wang H; He J; Su C; Yu Q
Front Oncol; 2021; 11():703143. PubMed ID: 34497760
[TBL] [Abstract][Full Text] [Related]
30. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.
Conforti F; Pala L; Pagan E; Corti C; Bagnardi V; Queirolo P; Catania C; De Pas T; Giaccone G
ESMO Open; 2021 Oct; 6(5):100251. PubMed ID: 34455288
[TBL] [Abstract][Full Text] [Related]
31. Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
Duchemann B; Remon J; Naigeon M; Cassard L; Jouniaux JM; Boselli L; Grivel J; Auclin E; Desnoyer A; Besse B; Chaput N
Transl Lung Cancer Res; 2021 Jun; 10(6):2937-2954. PubMed ID: 34295689
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
Chen M; Xu Y; Zhao J; Li J; Liu X; Zhong W; Wang M
Thorac Cancer; 2021 Sep; 12(17):2339-2344. PubMed ID: 34291566
[TBL] [Abstract][Full Text] [Related]
33. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
34. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Forest F; Casteillo F; Da Cruz V; Yvorel V; Picot T; Vassal F; Tiffet O; Péoc'h M
Lung Cancer; 2021 May; 155():1-9. PubMed ID: 33690015
[TBL] [Abstract][Full Text] [Related]
36. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
37. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Nokin MJ; Ambrogio C; Nadal E; Santamaria D
Trends Cancer; 2021 May; 7(5):410-429. PubMed ID: 33309239
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Zheng Q; Huang Y; Zeng X; Chen X; Shao S; Jin Y; Xue Q; Wang Y; Guo Y; Gu B; Wu C; Li Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1547-1556. PubMed ID: 33196892
[TBL] [Abstract][Full Text] [Related]
39. Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
Li JJN; Karim K; Sung M; Le LW; Lau SCM; Sacher A; Leighl NB
Lung Cancer; 2020 Dec; 150():159-163. PubMed ID: 33171404
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.
Peng L; Qin BD; Xiao K; Xu S; Yang JS; Zang YS; Stebbing J; Xie LP
Oncoimmunology; 2020 Jun; 9(1):1781333. PubMed ID: 32923143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
